DDrare: Database of Drug Development for Rare Diseases

Searched query = "Sarcoidosis"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.

Drug = 1% lignocaine; 13NH3 PET/CT scan; 18F-FDG; 18F-FSPG; 18F-fluorodeoxyglucose; 18FDG PET/CT scan; 2% lignocaine; 68Ga-DOTANOC; 68Ga-DOTATATE; 68Ga-DOTATATE PET/CT; 99m technetium infliximab; 99mTc-Infliximab; ABPC; ACT-293987 / JNJ-67896049; ACTHAR Gel (adrenocorticotropic hormone); ACTHAR Gel 40 units twice weekly; ACTHAR Gel 80 units twice weekly.; ACZ885; AMPC; ARA 290; ATYR1923; ATYR1923 1.0 mg/kg; ATYR1923 3.0 mg/kg; ATYR1923 5.0 mg/kg; Abatacept; Acthar; Acthar Gel; Acthar gel; Adalimumab; Adrenocorticotropic hormone; All subjects will receive maraviroc 300mg orally twice a day for 6 weeks; Allogeneic stem cell transplantation; Ambrisentan; Anakinra; Analysis of gamma globulin; Antibiotic Regimen; Antituberculous therapy along with steroids; Armodafinil; Atorvastatin; Autologous hematopoietic stem cell transplantation; Azithromycin; Azithromycin 250Mg Capsule; Azithromycin monohydrate; BAL; Bardoxolone; Bardoxolone methyl; Blood sample; Bosentan; Bosentan monohydrate; C11-methionine; CC; CC-100004; CC-220; CC-220 0.3 mg Daily; CC-220 0.6mg Daily; CMK389; CNTO 148; CNTO1275; CNTO148; Calcium; Calcium Citrate with Vitamin D2; Calcium citrate; Canakinumab; Ciclesonide; Clarithromycin; Corticosteroid; Corticotropin; Cu-64 DOTATATE; Cyclophosphamide; Cysteine; D-methylphenidate; DELTACORTENE*10CPR 25MG; DEXAMETHASONE; DOTANOC; Dapsone; Device: Blood pressure; Device: Flexible bronchoscopy in moderate sedation; Device: Nested PCR for formalin-fixed tissues; Device: Nested PCR for fresh tissues; Device: Oxygen saturation; Device: Propofol dosage; Device: Real-time PCR for fresh tissues; Device: Recovery time after bronchoscopy; Dexamethasone; Dexamethasone 0,5mg; Diagnostic Test: 18F-FDG-PET/MRI; Diagnostic Test: 18F-GE180-PET/MRI; Diagnostic Test: 68Ga-DOTA-TOC PET/CT; Diagnostic Test: FDG-PET/CT with Rb82 Myocardial Perfusion Imaging; Diagnostic Test: Laboratory testing; Diagnostic Test: Spirometry; Diagnostic Test: simultaneous combined 18F-FDG PET and cardiac MRI imaging; Dotatate; Doxycycline; Ergocalciferol; Ethambutol; FDG; FLUORINE (18F) FLUDEOXYGLUCOSE; Fermented oyster extract; Fludeoxyglucose; Fluorodeoxyglucose; Folic acid; Formalin; Ga-68-DOTA-NOC; Gallium-68 DOTATATE; Gallium-68-DOTA-N-Octreotide; Genetic: RNA Sequencing; Glucocorticoid (prednisone or prednisolone); Gold; Golimumab; Golimumab Liquid in prefilled syringe; H.P. Acthar Gel; Habitrol; Heparin; Human anti TNF-alpha monoclonal antibody; Human anti-IL 12/23 monoclonal antibody; Humira; Hydroxychloroquine; Hydroxychloroquine + Prednisone; ILARIS; IMod.Fc, H-Fcv3-N4; Ilaris; Iloprost; Indium; Indium-111 Pentreotide; Infliximab; Influenza Vaccine; Inhaled Treprostinil; L-METHIONINE ([11C]METHYL); L-methionine; Levaquin; Levofloxacin; Lignocaine; Low dose prednisolone; METHOTREXATE; MTX; Maraviroc; Medium dose prednisolone; Methionine; Methotrexate; Methylphenidate; Methylphenidate (overencapsulated); Methylphenidate 10mg tablets; Methylprednisolone; Methylprednisolone bolus IV 15 mg/kg/d for 3 days.; Minomycin; Mycophenolate; N-acetyl-cysteine; Nelutri™; Nicotine; Nicotine patch; None; OCTREOTIDE; ORENCIA; Octreotide; Octreotide LAR / Sandostatin LAR (LAR=long acting release); Orencia; Other: 18F-FDG; Other: 18F-Fluorodeoxyglucose (18F-FDG) PET/CT; Other: Normal Saline for injection; Oxygen; Oyster; PD 0360324; PDA001 (cenplacel-L); PLAQUENIL*25CPR RIV 200MG; PREDNISONE; Pentoxifylline; Pirfenidone; Prednisolone; Prednison; Prednisone; Procedure: Bronchoalveolar lavage (BAL); Procedure: Bronchoscopy with bronchoalveolar lavage; Procedure: EBB + TBLB + BAL; Procedure: EBUS guided transbronchial forceps biopsy (EBUS-TBFB); Procedure: EBUS guided transbronchial needle aspiration (EBUS-TBNA); Procedure: EUS-FNA/EBUS-TBNA + BAL; Procedure: Endobronchial forceps biopsy; Procedure: Skin biopsy; Procedure: large bore (19G) histologic needle biopsy of the mediastinal lymph nodes; Procedure: venipunctures; Propofol; Quercetin; Radiation: Rubidium PET; Rapamune; Remicade; Repository Corticotropin Injection; Repository Corticotropin Injection -Treatment Extension; Rifampin; Rifampin and azithromycin.; Riociguat; Rituximab; Roflumilast; Rubidium; SELEXIPAG; SIROLIMUS; Sandostatin LAR; Sarilumab; Sarilumab 200 MG/1.14 ML Subcutaneous Solution [KEVZARA]_#1; Schisandra chinensis extract; Seasonal influenza vaccine available for the 2012-2013 vaccine campaign; Selexipag; Sirolimus; Sirolimus Ointment; THALIDOMIDE; Tadalafil; Thalidomide; Tofacitinib; Tofacitinib 5 mg twice daily; Tofacitinib 5mg Oral Tablet [Xeljanz] 16 week trial; Tofacitinib 5mg [Xeljanz] 1 year open-label extension; Tracleer; Tranilast; Treprostinil; Uptravi; Ursodeoxycholic Acid; Ursodeoxycholic acid; Ustekinumab; Ustekinumab liquid in prefilled syringe; Vitamin D2; Water

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT02523092 (ClinicalTrials.gov)	October 2020	10/8/2015	Use of CXCL9 as a Biomarker of Acthar Efficacy	Use of CXCL9 as a Biomarker of Acthar Efficacy	Sarcoidosis	Drug: Acthar gel	University of California, San Francisco	Mallinckrodt	Not yet recruiting	18 Years	65 Years	All	14	Phase 4	United States
2	NCT02920710 (ClinicalTrials.gov)	February 1, 2019	29/9/2016	ACTHAR Therapy for Central Nervous System Sarcoidosis	ACTHAR Therapy for Central Nervous System Sarcoidosis	Sarcoidosis	Drug: Repository Corticotropin Injection	The Cleveland Clinic	Mallinckrodt	Withdrawn	N/A	N/A	All	0	Phase 4	United States
3	NCT03320070 (ClinicalTrials.gov)	January 24, 2018	20/10/2017	Acthar Gel in Participants With Pulmonary Sarcoidosis	A Phase 4, Multicenter, Randomized, Double Blind, Placebo Controlled Pilot Study to Assess the Efficacy and Safety of Acthar Gel in Subjects With Pulmonary Sarcoidosis	Sarcoidosis, Pulmonary	Drug: Acthar Gel;Drug: Placebo	Mallinckrodt	NULL	Active, not recruiting	18 Years	90 Years	All	55	Phase 4	United States
4	NCT02298491 (ClinicalTrials.gov)	May 2016	14/11/2014	CNS Sarcoidosis and Acthar Gel	Clinical Biomarkers of Disease Activity and Treatment Responses in Patients With CNS Sarcoidosis Treated With H.P. Acthar Gel	CNS Sarcoidosis	Drug: H.P. Acthar Gel	University of Maryland, Baltimore	Mallinckrodt	Completed	N/A	N/A	All	4	Phase 4	United States
5	NCT02725177 (ClinicalTrials.gov)	March 2016	11/3/2016	Ocular Sarcoidosis Open Label Trial of ACTHAR Gel	Ocular Sarcoidosis Open Label Trial of ACTHAR Gel	Ocular Sarcoidosis;Panuveitis;Anterior Uveitis	Drug: Repository Corticotropin Injection;Drug: Repository Corticotropin Injection -Treatment Extension	The Cleveland Clinic	Mallinckrodt	Recruiting	18 Years	99 Years	All	20	N/A	United States
No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
6	NCT02348905 (ClinicalTrials.gov)	March 2015	20/6/2014	ACTHAR Gel for Cutaneous Sarcoidosis: An Open Label Trial	ACTHAR Gel for Cutaneous Sarcoidosis: An Open Label Trial	Sarcoidosis;Cutaneous Sarcoidosis	Drug: ACTHAR Gel 40 units twice weekly;Drug: ACTHAR Gel 80 units twice weekly.	Albany Medical College	NULL	Not yet recruiting	18 Years	N/A	Both	10	Phase 2;Phase 3	United States
7	NCT02155803 (ClinicalTrials.gov)	February 2015	30/5/2014	ACTHAR GEL for Sarcoidosis-Associated Calcium Dysregulation: An Open-label Pilot Study	ACTHAR GEL for Sarcoidosis-Associated Calcium Dysregulation: An Open-label Pilot Study	Sarcoidosis;Hypercalcemia Due to Sarcoidosis	Drug: ACTHAR Gel (adrenocorticotropic hormone)	Albany Medical College	NULL	Not yet recruiting	18 Years	N/A	Both	10	Phase 2;Phase 3	United States
8	NCT02188017 (ClinicalTrials.gov)	June 2014	24/4/2014	Acthar Gel for Chronic Pulmonary Sarcoidosis (ACPS)	ACTHAR Gel for Chronic Pulmonary Sarcoidosis (ACPS)	Sarcoidosis;Pulmonary Sarcoidosis	Drug: Acthar gel	University of Cincinnati	Mallinckrodt	Recruiting	18 Years	90 Years	Both	20	Phase 4	United States

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

NCT02523092
(ClinicalTrials.gov)

October 2020

10/8/2015

Use of CXCL9 as a Biomarker of Acthar Efficacy

Sarcoidosis

Drug: Acthar gel

University of California, San Francisco

Mallinckrodt

Not yet recruiting

18 Years

65 Years

All

Phase 4

United States

NCT02920710
(ClinicalTrials.gov)

February 1, 2019

29/9/2016

ACTHAR Therapy for Central Nervous System Sarcoidosis

Sarcoidosis

Drug: Repository Corticotropin Injection

The Cleveland Clinic

Mallinckrodt

Withdrawn

N/A

All

Phase 4

United States

NCT03320070
(ClinicalTrials.gov)

January 24, 2018

20/10/2017

Acthar Gel in Participants With Pulmonary Sarcoidosis

A Phase 4, Multicenter, Randomized, Double Blind, Placebo Controlled Pilot Study to Assess the Efficacy and Safety of Acthar Gel in Subjects With Pulmonary Sarcoidosis

Sarcoidosis, Pulmonary

Drug: Acthar Gel;Drug: Placebo

Mallinckrodt

NULL

Active, not recruiting

18 Years

90 Years

All

Phase 4

United States

NCT02298491
(ClinicalTrials.gov)

May 2016

14/11/2014

CNS Sarcoidosis and Acthar Gel

Clinical Biomarkers of Disease Activity and Treatment Responses in Patients With CNS Sarcoidosis Treated With H.P. Acthar Gel

CNS Sarcoidosis

Drug: H.P. Acthar Gel

University of Maryland, Baltimore

Mallinckrodt

Completed

N/A

All

Phase 4

United States

NCT02725177
(ClinicalTrials.gov)

March 2016

11/3/2016

Ocular Sarcoidosis Open Label Trial of ACTHAR Gel

Ocular Sarcoidosis;Panuveitis;Anterior Uveitis

Drug: Repository Corticotropin Injection;Drug: Repository Corticotropin Injection -Treatment Extension

The Cleveland Clinic

Mallinckrodt

Recruiting

18 Years

99 Years

All

N/A

United States

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

NCT02348905
(ClinicalTrials.gov)

March 2015

20/6/2014

ACTHAR Gel for Cutaneous Sarcoidosis: An Open Label Trial

Sarcoidosis;Cutaneous Sarcoidosis

Drug: ACTHAR Gel 40 units twice weekly;Drug: ACTHAR Gel 80 units twice weekly.

Albany Medical College

NULL

Not yet recruiting

18 Years

N/A

Both

Phase 2;Phase 3

United States

NCT02155803
(ClinicalTrials.gov)

February 2015

30/5/2014

ACTHAR GEL for Sarcoidosis-Associated Calcium Dysregulation: An Open-label Pilot Study

Sarcoidosis;Hypercalcemia Due to Sarcoidosis

Drug: ACTHAR Gel (adrenocorticotropic hormone)

Albany Medical College

NULL

Not yet recruiting

18 Years

N/A

Both

Phase 2;Phase 3

United States

NCT02188017
(ClinicalTrials.gov)

June 2014

24/4/2014

Acthar Gel for Chronic Pulmonary Sarcoidosis (ACPS)

ACTHAR Gel for Chronic Pulmonary Sarcoidosis (ACPS)

Sarcoidosis;Pulmonary Sarcoidosis

Drug: Acthar gel

University of Cincinnati

Mallinckrodt

Recruiting

18 Years

90 Years

Both

Phase 4

United States